Published in Infect Immun on December 01, 2003
The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog (2010) 1.81
Review of meningococcal group B vaccines. Clin Infect Dis (2010) 1.58
Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis (2005) 1.25
Characterization of MspA, an immunogenic autotransporter protein that mediates adhesion to epithelial and endothelial cells in Neisseria meningitidis. Infect Immun (2006) 1.07
posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate. Infect Immun (2005) 1.06
The relative roles of factor H binding protein, neisserial surface protein A, and lipooligosaccharide sialylation in regulation of the alternative pathway of complement on meningococci. J Immunol (2012) 1.04
Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J Immunol (2011) 0.99
Expression of heterologous antigens in commensal Neisseria spp.: preservation of conformational epitopes with vaccine potential. Infect Immun (2004) 0.92
Comparative proteome analysis of spontaneous outer membrane vesicles and purified outer membranes of Neisseria meningitidis. J Bacteriol (2013) 0.89
Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clin Vaccine Immunol (2008) 0.85
Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice. Infect Immun (2015) 0.78
Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice. Clin Vaccine Immunol (2011) 0.78
Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res (2003) 38.75
Meningococcal disease. N Engl J Med (2001) 8.50
Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet (1983) 5.63
The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis (1999) 4.37
Single bilayer liposomes prepared without sonication. Biochim Biophys Acta (1973) 3.83
Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA. Microb Pathog (1988) 2.75
Development of vaccines against meningococcal disease. Lancet (2002) 2.67
Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun (2001) 2.16
Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med (1997) 1.76
Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun (1999) 1.76
Crystal structure of Neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential. J Biol Chem (2003) 1.54
Sequence diversity, predicted two-dimensional protein structure, and epitope mapping of neisserial Opa proteins. J Bacteriol (1998) 1.53
Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopeptides. J Infect Dis (1995) 1.47
Meningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6-8 October, 2000. Vaccine (2001) 1.34
Vaccine prevention of meningococcal disease, coming soon? Vaccine (2001) 1.31
Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun (2002) 1.29
A novel mimetic antigen eliciting protective antibody to Neisseria meningitidis. J Immunol (2001) 1.28
Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun (2001) 1.21
Crystal structure of the OpcA integral membrane adhesin from Neisseria meningitidis. Proc Natl Acad Sci U S A (2002) 1.14
Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun (1999) 1.03
Two-dimensional structure of the Opc invasin from Neisseria meningitidis. Mol Microbiol (1997) 0.97
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol (2006) 3.62
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
Development of vaccines against meningococcal disease. Lancet (2002) 2.67
Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet (2003) 2.21
Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol (2004) 2.13
Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J Infect Dis (2008) 2.00
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol (2011) 1.68
Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun (2008) 1.66
Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun (2008) 1.61
Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine (2009) 1.42
Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine. J Infect Dis (2006) 1.39
Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun (2002) 1.29
Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun (2011) 1.29
Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development. PLoS Negl Trop Dis (2011) 1.27
Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870. J Infect Dis (2005) 1.25
Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin Vaccine Immunol (2009) 1.24
The modular architecture of meningococcal factor H-binding protein. Microbiology (2009) 1.24
Meningococcal outer membrane vesicle vaccines derived from mutant strains engineered to express factor H binding proteins from antigenic variant groups 1 and 2. Clin Vaccine Immunol (2008) 1.22
Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis (2008) 1.19
Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. Mol Microbiol (2006) 1.17
The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog (2012) 1.17
Age-related disparity in functional activities of human group C serum anticapsular antibodies elicited by meningococcal polysaccharide vaccine. Infect Immun (2003) 1.12
Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun (2010) 1.11
Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen. Vaccine (2011) 1.11
Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine. J Infect Dis (2007) 1.08
Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis. Infect Immun (2011) 1.06
Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun (2011) 1.06
Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine (2013) 1.05
Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate. Clin Vaccine Immunol (2006) 1.04
Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis. MBio (2013) 1.02
Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis (2013) 1.01
Are drug companies living up to their human rights responsibilities? Moving toward assessment. PLoS Med (2010) 1.01
Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine (2011) 1.00
Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun (2012) 0.99
Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol (2010) 0.98
A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp. Sci Rep (2012) 0.97
A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol (2011) 0.97
Improved immunogenicity of a H44/76 group B outer membrane vesicle vaccine with over-expressed genome-derived Neisserial antigen 1870. Vaccine (2006) 0.96
Highly conserved Neisseria meningitidis inner-core lipopolysaccharide epitope confers protection against experimental meningococcal bacteremia. J Infect Dis (2003) 0.92
Molecular analysis of anti-N-propionyl Neisseria meningitidis group B polysaccharide monoclonal antibodies. Mol Immunol (2005) 0.90
Epitopes recognized by a nonautoreactive murine anti-N-propionyl meningococcal group B polysaccharide monoclonal antibody. Infect Immun (2005) 0.90
Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity. PLoS One (2012) 0.89
Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants. Pediatr Infect Dis J (2004) 0.89
Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa. PLoS One (2013) 0.86
Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect Immun (2014) 0.86
Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants. Pediatr Infect Dis J (2003) 0.86
Priming for immunologic memory in adults by meningococcal group C conjugate vaccination. Clin Vaccine Immunol (2006) 0.85
Naturally-acquired immunity to Neisseria meningitidis group A. Vaccine (2005) 0.84
Human rights in health systems frameworks: what is there, what is missing and why does it matter? Glob Public Health (2012) 0.84
Effect of human serum on de-N-acetyl sialic acid epitope expression and antibody activity against N. meningitidis group B. Vaccine (2010) 0.83
Identification of a phage-encoded Ig-binding protein from invasive Neisseria meningitidis. J Immunol (2013) 0.82
Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization. J Infect Dis (2006) 0.82
fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations. Vaccine (2013) 0.82
Immune status of infants fed soy-based formulas with or without added nucleotides for 1 year: part 1: vaccine responses, and morbidity. J Pediatr Gastroenterol Nutr (2002) 0.80
Evidence for rosettes as an unrecognized stage in the life cycle of Leishmania parasites. J Eukaryot Microbiol (2010) 0.78
Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic. Pediatr Infect Dis J (2004) 0.78
An antibody to de-N-acetyl sialic acid containing-polysialic acid identifies an intracellular antigen and induces apoptosis in human cancer cell lines. PLoS One (2011) 0.77
Safety and immunogenicity of haemophilus influenzae type B polysaccharide or conjugate vaccines in an elderly adult population. J Am Geriatr Soc (2004) 0.77
Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan. Hum Vaccin (2007) 0.76
Thoracic gas compression during forced expiration in patients with emphysema, interstitial lung disease and obesity. BMC Pulm Med (2014) 0.75
The expression profile of de-N-acetyl polysialic acid (NeuPSA) in normal and diseased human tissue. J Biol Chem (2011) 0.75